Literature DB >> 23064399

Tenascin-C in cardiovascular tissue remodeling: from development to inflammation and repair.

Kyoko Imanaka-Yoshida1.   

Abstract

Tenascin-C (TN-C) is a matricellular protein expressed during embryonic development, as well as in wound healing and cancer invasion in various tissues, and may regulate cell behavior and matrix organization during tissue remodeling. In the cardiovascular system, TN-C is transiently expressed at several important steps of embryonic development, playing important roles in the differentiation of cardiomyocytes and in coronary vasculo/angiogenesis. TN-C is sparse in normal adults, but upregulated under pathological conditions such as myocarditis, myocardial infarction, cardiac fibrosis, atherosclerosis, stenotic neointimal hyperplasia, and aneurysm, and is closely associated with tissue injury and inflammation. In view of its specific expression, TN-C could be a realistic and promising biomarker and a target for molecular imaging for the diagnosis of various cardiovascular diseases. TN-C also has diverse functions, including weakening of cell adhesion, up-regulating the expression and activity of matrix metalloproteinases, modulating inflammatory responses, promoting recruitment of myofibroblasts, and enhancing fibrosis. TN-C could exert both harmful and protective effects and might be a therapeutic target as a key molecule in the control of the balance of beneficial and undesirable cellular responses during tissue remodeling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23064399     DOI: 10.1253/circj.cj-12-1033

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  43 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

2.  Tenascin-C protects against acute kidney injury by recruiting Wnt ligands.

Authors:  Shuangqin Chen; Haiyan Fu; Songzhao Wu; Wenjuan Zhu; Jinlin Liao; Xue Hong; Jinhua Miao; Congwei Luo; Yongping Wang; Fan Fan Hou; Lili Zhou; Youhua Liu
Journal:  Kidney Int       Date:  2018-11-06       Impact factor: 10.612

Review 3.  Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Authors:  Marcus Franz; Christian Jung; Alexander Lauten; Hans R Figulla; Alexander Berndt
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

4.  Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade.

Authors:  Shuichi Fujita; Naoshi Shimojo; Fumio Terasaki; Kaoru Otsuka; Noriko Hosotani; Yuka Kohda; Takao Tanaka; Tomohiro Nishioka; Toshimichi Yoshida; Michiaki Hiroe; Yasushi Kitaura; Nobukazu Ishizaka; Kyoko Imanaka-Yoshida
Journal:  Heart Vessels       Date:  2013-01-01       Impact factor: 2.037

5.  Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis.

Authors:  Hiroe Toba; Presley L Cannon; Andriy Yabluchanskiy; Rugmani Padmanabhan Iyer; Jeanine D'Armiento; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-23       Impact factor: 4.733

6.  Bone Marrow-Derived Tenascin-C Attenuates Cardiac Hypertrophy by Controlling Inflammation.

Authors:  Lei Song; Lai Wang; Fuqiang Li; Ada Yukht; Minghui Qin; Haley Ruther; Mingjie Yang; Aurelio Chaux; Prediman K Shah; Behrooz G Sharifi
Journal:  J Am Coll Cardiol       Date:  2017-09-26       Impact factor: 24.094

Review 7.  Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.

Authors:  Alexander Berndt; Petra Richter; Hartwig Kosmehl; Marcus Franz
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

8.  Integrin α9 on lymphatic endothelial cells regulates lymphocyte egress.

Authors:  Koyu Ito; Junko Morimoto; Akio Kihara; Yutaka Matsui; Daisuke Kurotaki; Masashi Kanayama; Szandor Simmons; Masaru Ishii; Dean Sheppard; Akinori Takaoka; Toshimitsu Uede
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

9.  Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.

Authors:  Barnabas Gellen; Nathalie Thorin-Trescases; Eric Thorin; Elise Gand; Philippe Sosner; Sonia Brishoual; Vincent Rigalleau; David Montaigne; Vincent Javaugue; Yann Pucheu; Philippe Gatault; Xavier Piguel; Samy Hadjadj; Pierre-Jean Saulnier
Journal:  Diabetologia       Date:  2020-02-10       Impact factor: 10.122

Review 10.  Tenascin-C in Heart Diseases-The Role of Inflammation.

Authors:  Kyoko Imanaka-Yoshida
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.